Validation of a wrist-worn device for the assessment of energy expenditure in patients with chronic heart failure and coronary artery disease

Validation of a wrist-worn device for the assessment of energy expenditure in patients with chronic heart failure and coronary artery disease - -

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45827

Enrollment

Registered

2017-05-29

Start date

2017-10-11

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure congestive heart failure

Interventions

Chronic heart failure

Coronary artery disease

Energy expenditure

Fitbit Charge 2

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria heart failure patients: - Minimum age 18 years - Patients with heart failure with reduced ejection fraction (LVEF

Exclusion criteria

Exclusion criteria: Exclusion criteria heart failure patients: - Hemodynamically significant valvular disease - Atrial fibrillation - Peripheral vascular, neurological and orthopaedic conditions impairing exercise capacity - Severe psychological or cognitive impairments;Exclusion criteria patients with coronary artery disease: - Left ventricular ejection fraction

Design outcomes

Primary

Measure	Time frame
The primary objective of the present study is to determine the accuracy of a wrist-worn activity tracker (Fitbit Charge 2) for the assessment of energy expenditure (kcal/min) during daily living activities in patients with stable coronary artery disease and chronic heart failure NYHA Class II-III, LVEF	—

Secondary

Measure	Time frame
The secondary objective of the present study is to determine the accuracy of Fitbit Charge 2 in measuring energy expenditure (kcal/minute) in walking and cycling activities, in patients with stable coronary artery disease and heart failure NYHA Class II-III, LVEF	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)